Skip to main content
SpringerLink
Log in

Research governance at the crossroads

  • Commentary
  • Published:

From Nature Medicine

View current issue Submit your manuscript

A few, high profile disasters in clinical trials in recent years have thrust the area of human subject research into the regulatory spotlight. The US has been quickest to react to public concern by introducing systems to tighten-up oversight mechanisms. The UK is now examining its clinical policies and here the authors question the best way forrward.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Author information

Authors and Affiliations

  1. School of Medicine, Imperial College, London, UK

    Andrew J.T. George & Robert Winston

  2. Research Governance Hammersmith Hospital, London, UK

    Rodney Gale

  3. Biomedical and Health Sciences Research Association of American Academic Medical Colleges, Washington, DC, USA

    David Korn

Authors
  1. Andrew J.T. George
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rodney Gale
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert Winston
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. David Korn
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

George, A., Gale, R., Winston, R. et al. Research governance at the crossroads. Nat Med 8, 99–101 (2002). https://doi.org/10.1038/nm0202-99

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0202-99

  • Springer Nature America, Inc.

Search

Navigation